MolecularMD Enters Into a Collaboration Agreement With Illumina for Drug-Diagnostic Co-Development With Biopharma Drug Programs
27. Juni 2016 12:00 ET
|
MolecularMD
PORTLAND, OR and CAMBRIDGE, MA--(Marketwired - June 27, 2016) - MolecularMD Corporation announced today that it has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN) that establishes a...
MolecularMD Has Obtained CE Marking of a Diagnostic Assay Developed for a Daiichi Sankyo, Inc. Phase II Clinical Trial
25. April 2016 07:35 ET
|
MolecularMD
PORTLAND, OR and CAMBRIDGE, MA--(Marketwired - April 25, 2016) - MolecularMD Corp., a molecular diagnostics company that accelerates oncology drug development by providing custom companion...
MolecularMD Receives New York State Approval for Next Generation Sequencing Test to Support Clinical Trial Enrollment
16. Juli 2015 10:17 ET
|
MolecularMD
PORTLAND, OR and CAMBRIDGE, MA--(Marketwired - Jul 16, 2015) - MolecularMD Corp., a molecular diagnostics company that provides companion diagnostic solutions and supporting clinical trial...
MolecularMD Receives ISO Certification for Design, Development and Production of Molecular Diagnostic Products
26. März 2015 00:05 ET
|
MolecularMD
PORTLAND, OR and CAMBRIDGE, MA--(Marketwired - Mar 26, 2015) - MolecularMD Corp., a molecular diagnostics company that develops custom companion diagnostics and provides clinical trial testing...
MolecularMD Cambridge Laboratory Receives CAP Accreditation With Focus on NGS Panels for Clinical Trial Enrollment and NGS Liquid Biopsy Testing
17. Dezember 2014 22:24 ET
|
MolecularMD
PORTLAND, OR and CAMBRIDGE, MA--(Marketwired - Dec 17, 2014) - MolecularMD, Corp., a molecular diagnostics company that develops custom companion diagnostic products and supports clinical trial...
MolecularMD Develops Notch1 Next Generation Sequencing Test to Support Clinical Development for OncoMed's Anti-Notch1 Antibody, OMP-52M51
12. Juni 2014 07:54 ET
|
MolecularMD
PORTLAND, OR and CAMBRIDGE, MA--(Marketwired - Jun 12, 2014) - MolecularMD Corp., a molecular diagnostics company that provides custom companion diagnostic solutions and supporting clinical trial...
MolecularMD Receives CLIA Certification for Its Second Next Generation Sequencing Laboratory
04. April 2014 07:00 ET
|
MolecularMD
PORTLAND, OR and CAMBRIDGE, MA--(Marketwired - Apr 4, 2014) - MolecularMD, Inc., a molecular diagnostics company that provides custom companion diagnostic solutions and supporting clinical trial...
MolecularMD Launches NanoString Platform for Multiplexed Digital Evaluation of Gene Expression and Copy Number Variation in Clinical Specimens
05. März 2014 07:00 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - Mar 5, 2014) - MolecularMD Corp. today announced that it has launched the NanoString nCounter® Analysis System for multiplex biomarker evaluation in support of...
MolecularMD to Develop Highly Sensitive Companion Diagnostic Test to Support CML Treatment Free Remission Clinical Trials
19. Februar 2014 07:00 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - Feb 19, 2014) - MolecularMD Corp. today announced that it has entered into a collaboration with Novartis Pharmaceuticals Corporation to develop a companion diagnostic...
MolecularMD Announces Presentations at Upcoming American Society of Hematology Annual Meeting
05. Dezember 2013 07:00 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - Dec 5, 2013) - MolecularMD Corp., a molecular diagnostics company focused on providing the highest quality companion diagnostics and clinical trials support services to...